MOTS-c: What the Evidence Actually Shows

MOTS-c is usually pitched as "exercise in a vial" — a mitochondrial signal that mimics what a hard workout does to your metabolism, marketed for fat loss, insulin sensitivity, and healthy aging. One part of that pitch is genuinely unusual and worth taking seriously on its own terms: MOTS-c really is encoded somewhere almost no other marketed peptide is, inside mitochondrial DNA itself rather than the cell's nuclear genome. What's less straightforward is the evidence question everything else depends on. This isn't a story like KPV's, where the human literature turns out to be empty. Real, published, human-subject research on MOTS-c exists — several studies have measured it directly in people's blood and muscle. But nearly all of that research measures a person's own naturally occurring MOTS-c level, not a synthetic dose administered as a drug. The one completed human trial that did inject a MOTS-c-family peptide into people used a different molecule, made by a different company, for a different condition than what FDA's advisory committee actually reviewed MOTS-c for. This article traces the animal evidence, the human evidence exactly as it was actually measured, and the current regulatory record to their real sources — and keeps those three things separate throughout, because collapsing them is the easiest way to overstate what's known.

What MOTS-c actually is

Start with the genuinely distinctive fact. Every cell carries two separate genomes: the large nuclear genome in the cell's nucleus, and a much smaller, separate, circular genome inside the mitochondria themselves — a roughly 16,500-base-pair loop of DNA, inherited only from your mother, that mitochondria have retained since their evolutionary origin as free-living bacteria that were absorbed into larger cells billions of years ago². Almost every other peptide covered on this site traces back to a gene in that first, nuclear genome. MOTS-c does not. In 2015, researchers at USC's Leonard Davis School of Gerontology reported a short open reading frame — a small stretch of protein-coding instructions — sitting inside the mitochondrial genome's 12S rRNA region, a part of the mitochondrial DNA not previously known to code for its own independent signaling molecule. That reading frame translates into a 16-amino-acid peptide the researchers named MOTS-c, for "mitochondrial open reading frame of the 12S rRNA — type c"¹. A follow-up review from the same lab frames MOTS-c as only the second mitochondrial-DNA-encoded signaling peptide identified at the time, after a peptide called humanin — evidence, the authors argue, that mitochondria carry a "larger mitochondrial genetic repertoire" than previously appreciated, capable of sending its own hormone-like signals to the rest of the body rather than only running cellular energy production².

Mechanistically, the discovery paper's own results describe MOTS-c's primary target as skeletal muscle, working by inhibiting the folate cycle and the purine-building pathway tethered to it, which in turn activates AMPK — a central cellular energy-sensing enzyme that gets switched on by exactly the kind of metabolic stress vigorous exercise produces¹. A later study studying MOTS-c's effect on metformin (a different AMPK-pathway drug) in cancer patients describes the same route more specifically as "the folate-AICAR-AMPK pathway"⁷. That AMPK connection is the biological basis for calling MOTS-c an "exercise mimetic": the argument isn't that MOTS-c does something exercise can't, but that it appears to flip the same metabolic switch exercise flips, at least in the tissues and species tested so far.

What the animal evidence actually shows

The animal literature here is real and, unlike some peptides in this space, comes from a small number of well-credentialed labs building directly on the original discovery rather than a scattered set of unrelated groups. Representative findings, read from the studies' own results sections:

• •Original discovery, mice (2015). In the same paper that identified MOTS-c's mitochondrial origin, "MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity"¹.
• •Physical performance and healthspan, mice across the lifespan (2021). A follow-up study from the same research group reported that MOTS-c "significantly enhanced physical performance" in young (2-month), middle-age (12-month), and old (22-month) mice, and that starting intermittent MOTS-c treatment late in life (23.5 months, roughly equivalent to advanced old age in a mouse) still increased both physical capacity and overall healthspan³.
• •Bone metabolism, preclinical synthesis (2023). A review of the accumulated cell-culture and rodent literature reports that MOTS-c "promotes osteoblast proliferation, differentiation, and mineralization" (the bone-building cell line) while inhibiting osteoclast production (the bone-resorbing cell line) — the biological rationale behind osteoporosis being one of the two uses FDA's advisory committee specifically evaluated MOTS-c for in 2026⁹. Worth flagging for anyone researching this specific claim further: an earlier, frequently-cited paper on MOTS-c and bone-fracture healing was formally retracted by its publisher in 2021 over image-integrity problems in the original manuscript — a reminder to check a paper's current retraction status, not just its abstract, before treating it as evidence.

That's a genuinely coherent preclinical story — metabolic, physical-performance, and bone-biology effects, replicated across multiple studies from an identifiable research lineage, entirely in mice and cultured cells. None of it is a claim about what a compounded product does in a person.

What the human evidence actually shows

This is where precision matters most, because the honest answer is more complicated than a flat "no human data" — and more complicated than the marketing framing too. A live search turns up several real, published, human-subject MOTS-c studies. Every one of them measures something different from what a drug trial measures: a person's own naturally occurring, endogenous MOTS-c level in blood or muscle tissue, not a synthetic peptide dosed into them.

• •Exercise raises endogenous MOTS-c — sometimes, and not by much. The same 2021 study that reported MOTS-c's mouse healthspan effects also included a human observational arm, reporting that "exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation"³. A separate, smaller randomized study measuring this more precisely found a more modest picture: after a single bout of endurance exercise, circulating MOTS-c "showed a trend to increase" — explicitly not reported as statistically significant — while resistance exercise produced no such trend, and plasma MOTS-c levels weren't correlated with fitness measures like VO2max or leg strength at all⁴. A 16-week supervised aerobic-and-resistance program in breast cancer survivors found MOTS-c rose significantly after exercise in non-Hispanic White participants specifically, but not in Hispanic participants in the same program — a difference the study's authors attribute to ethnicity-linked variation in mitochondrial DNA itself⁵. And a 2025 study found repeated heat exposure — not exercise, and not the muscle immobilization the study was actually testing — raised circulating MOTS-c in physically active men⁶. Read together, these studies indicate endogenous MOTS-c is a real, measurable, exercise-and-stress-responsive human biomarker, but an inconsistent one whose response depends heavily on the specific stimulus and population studied — not a reliably reproducible signal every study finds.
• •Not every human study found an effect. In HER2-positive breast cancer patients, 24 weeks of chemotherapy and trastuzumab, with or without the anti-diabetic drug metformin (which activates a related metabolic pathway), produced no significant change in circulating MOTS-c either way⁷. And in 121 type 2 diabetics with coronary artery disease, low circulating MOTS-c was found to independently predict a roughly fourfold higher two-year risk of major adverse cardiac events — a genuine human finding, but a prognostic biomarker association in sick patients, not evidence that raising MOTS-c would change that risk⁸.

None of the studies above dosed anyone with synthetic MOTS-c. What they measured, in every case, is the level of MOTS-c a person's own mitochondria were already making. That is a meaningfully different category of evidence from a clinical trial of MOTS-c as a drug — real human data, worth taking seriously as biomarker research, but not evidence that injecting more of it produces the same effects as the body's own production does under exercise or stress.

The one human drug trial in this family belongs to a different molecule. A live search of ClinicalTrials.gov's own registry turns up exactly one completed interventional human trial anywhere in the MOTS-c discovery lineage: NCT03998514, a Phase 1a/1b study run by CohBar, Inc. — a biotechnology company co-founded by one of MOTS-c's original discoverers — testing single- and multiple-ascending subcutaneous doses of a compound called CB4211 in healthy non-obese volunteers and in people with nonalcoholic fatty liver disease (NAFLD). The trial completed April 19, 2021. Every arm and intervention in the registry record is named "CB4211" — never "MOTS-c"¹⁰. CohBar's own public materials describe CB4211 as a "novel analog" of MOTS-c: an engineered, modified version of the peptide, not the exact 16-amino-acid sequence mitochondrial DNA actually encodes, developed for a different condition (fatty liver disease) than the obesity-and-osteoporosis uses FDA's advisory committee evaluated native MOTS-c for in 2026. PubMed itself returns zero indexed results for "CB4211," confirming its evidence trail lives in the clinical-trial registry and company/industry coverage, not the peptide-chemistry literature. If a compounded product is sold as "MOTS-c," CB4211's Phase 1 safety data does not transfer to it — they are not the same molecule, from the same source, tested for the same thing.

The current FDA and compounding status

MOTS-c has never had an FDA-approved drug product. A direct, live check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for "MOTS-C." Its compounding status has moved recently, on the same track as several other research peptides: FDA placed MOTS-c in Category 2 of its interim 503A bulk-substances list — substances presenting significant safety risks that pharmacies should not compound — in 2023, then removed it from Category 2 on April 15, 2026 (effective April 22), alongside eleven other peptides including BPC-157, TB-500, and KPV, because the nomination behind that listing was withdrawn. That removal is a procedural change, not an FDA safety finding, and does not by itself make compounding MOTS-c legal¹¹.

On July 23, 2026, FDA's own Pharmacy Compounding Advisory Committee (PCAC) formally reviewed "MOTs-C-related bulk drug substances (MOTs-C (free base)/ MOTs-C acetate)" for inclusion on the 503A Bulks List. FDA's own "Uses evaluated" column for MOTS-c, read directly from its meeting page, is "Obesity and osteoporosis"¹² — the same nominated uses the bone-biology preclinical literature above is directly relevant to. The committee voted 7 in favor, 5 against, with 2 abstentions to recommend MOTS-c for the list — a narrower margin and more abstentions than BPC-157, TB-500, or KPV each received at the same two-day meeting, which independent regulatory-recap coverage of the hearing ties to MOTS-c's comparatively early-stage human evidence base relative to those other peptides¹¹. That is a recommendation, not a rule. Formal notice-and-comment rulemaking had not started as of this review, and one regulatory analysis estimates that process could extend into 2027 or beyond. As of this writing, MOTS-c has no approved product, no FDA-set dosing standard, and a compounding status that is recommended but not finalized.

What this means if you're considering a compounded MOTS-c product

Lay the record out and MOTS-c turns out to be a genuinely different case from the "animal-data-only, zero-human-evidence" pattern this site has found in some other peptides. The mouse literature is real and comes from an identifiable, credentialed research lineage tracing back to MOTS-c's own discovery. The human literature is real too — several published studies have measured MOTS-c directly in living people, most of them around exercise, and that's more than exists for some of MOTS-c's peptide-market neighbors. But every one of those human studies measured what a person's own body was already producing; none tested what happens when synthetic MOTS-c is injected into someone, at any dose, for any length of time. The single human interventional drug trial in this entire family used CB4211, a different sponsor's engineered analog, for a different condition than the obesity-and-osteoporosis uses FDA's committee actually reviewed MOTS-c for — its safety data describes CB4211, not what a compounding pharmacy would sell under the MOTS-c name.

That gap matters most for anyone weighing MOTS-c's "exercise mimetic" framing specifically: it's exactly the claim built on mouse data and human biomarker correlations, not on a human trial of the injected peptide itself. It also means there's no human dosing-safety record specific to native MOTS-c to weigh against a compounded product's own separate unknowns — actual purity, actual peptide content, contamination — the way even a thin clinical-trial literature at least gives a clinician-observed reference point. Our MOTS-c reconstitution calculator does the vial-to-syringe arithmetic and covers the current compounding-status caution in more detail; it does not, and cannot, supply human dosing-safety data for native MOTS-c, because — as of this review — that data doesn't exist. For comparison against other peptides in this same regulatory review cycle, see our evidence reviews of KPV, BPC-157, and TB-500.